Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "U.S.-generics-market"

4 News Found

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26
News | May 15, 2026

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity
Drug Approval | April 08, 2026

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Granules Pharmaceuticals secures FDA tentative approval and 180-day exclusivity for Generic Dyanavel XR
Drug Approval | January 09, 2026

Granules Pharmaceuticals secures FDA tentative approval and 180-day exclusivity for Generic Dyanavel XR

This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
News | July 24, 2025

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore

Latest Stories

Lupin receives USFDA nod for Famotidine injection

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
Dushyant Sapre Founder and CEO, SwishX
Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital
Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital
Duraisamy Rajan Palani Founder and CEO, Archimedis Digital
Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Packaging